Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| VACCINEX, INC.VCNX · Entity 9673 | Director | May 10, 2024 | May 14, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
VACCINEX, INC.
Report date May 10, 2024 · Filed May 14, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.75 · Expires 2034-05-10 | Direct | 2,211 |
Reported balance
After 2024-05-10 transaction · row 28
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 28 · 2024-05-10 · Grant · Acquired 2,211 · Balance 2,211 F9: Pursuant to the Issuer's Director Compensation Plan, in a transaction exempt under Rule 16b-3, the reporting person elected to receive these options in lieu of $8,750 for retainer and meeting fees during the first quarter of 2024. The number of options was calculated in accordance with the Black-Scholes valuation model and all such options are immediately exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.75 | Direct | 10,108 |
Reported balance
After 2024-05-10 transaction · row 29
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 29 · 2024-05-10 · Grant · Acquired 10,108 · Balance 10,108 F10: This option was granted pursuant to the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and expires on May 10, 2034 or five years following retirement or cessation of services, whichever occurs first. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2,856.00 · Expires 2027-09-15 | Direct | 30 |
Reported balance
Holding disclosure · report date 2024-05-10 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 30 F3: Exercisable in full as of the date of this report. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1,104.60 · Expires 2029-03-30 | Direct | 11 |
Reported balance
Holding disclosure · report date 2024-05-10 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 11 F3: Exercisable in full as of the date of this report. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1,633.80 | Direct | 36 |
Reported balance
Holding disclosure · report date 2024-05-10 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 36 F3: Exercisable in full as of the date of this report. F4: This option expires on May 14, 2029 or five years following retirement or cessation of services, whichever occurs first. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1,159.20 · Expires 2029-06-29 | Direct | 11 |
Reported balance
Holding disclosure · report date 2024-05-10 · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · Balance 11 F3: Exercisable in full as of the date of this report. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1,505.70 · Expires 2029-09-27 | Direct | 8 |
Reported balance
Holding disclosure · report date 2024-05-10 · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · Balance 8 F3: Exercisable in full as of the date of this report. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1,018.50 · Expires 2029-12-28 | Direct | 13 |
Reported balance
Holding disclosure · report date 2024-05-10 · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · Balance 13 F3: Exercisable in full as of the date of this report. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $840.00 · Expires 2030-03-29 | Direct | 15 |
Reported balance
Holding disclosure · report date 2024-05-10 · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · Balance 15 F3: Exercisable in full as of the date of this report. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $829.50 | Direct | 74 |
Reported balance
Holding disclosure · report date 2024-05-10 · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · Balance 74 F3: Exercisable in full as of the date of this report. F5: This option expires on May 12, 2030 or five years following retirement or cessation of services, whichever occurs first. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $758.10 · Expires 2030-06-28 | Direct | 17 |
Reported balance
Holding disclosure · report date 2024-05-10 · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · Balance 17 F3: Exercisable in full as of the date of this report. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $373.80 · Expires 2030-09-28 | Direct | 36 |
Reported balance
Holding disclosure · report date 2024-05-10 · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · Balance 36 F3: Exercisable in full as of the date of this report. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $434.70 · Expires 2030-12-29 | Direct | 31 |
Reported balance
Holding disclosure · report date 2024-05-10 · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · Balance 31 F3: Exercisable in full as of the date of this report. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $625.80 · Expires 2031-03-31 | Direct | 21 |
Reported balance
Holding disclosure · report date 2024-05-10 · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · Balance 21 F3: Exercisable in full as of the date of this report. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $451.50 | Direct | 136 |
Reported balance
Holding disclosure · report date 2024-05-10 · row 16
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 16 · Balance 136 F3: Exercisable in full as of the date of this report. F6: This option expires on May 9, 2031 or five years following retirement or cessation of services, whichever occurs first. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $588.00 · Expires 2031-06-28 | Direct | 22 |
Reported balance
Holding disclosure · report date 2024-05-10 · row 17
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 17 · Balance 22 F3: Exercisable in full as of the date of this report. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $453.60 · Expires 2031-09-28 | Direct | 29 |
Reported balance
Holding disclosure · report date 2024-05-10 · row 18
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 18 · Balance 29 F3: Exercisable in full as of the date of this report. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $218.40 · Expires 2031-12-29 | Direct | 61 |
Reported balance
Holding disclosure · report date 2024-05-10 · row 19
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 19 · Balance 61 F3: Exercisable in full as of the date of this report. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $277.20 · Expires 2032-03-28 | Direct | 47 |
Reported balance
Holding disclosure · report date 2024-05-10 · row 20
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 20 · Balance 47 F3: Exercisable in full as of the date of this report. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $235.20 | Direct | 253 |
Reported balance
Holding disclosure · report date 2024-05-10 · row 21
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 21 · Balance 253 F3: Exercisable in full as of the date of this report. F7: This option expires on May 9, 2032 or five years following retirement or cessation of services, whichever occurs first. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $226.80 · Expires 2032-06-27 | Direct | 57 |
Reported balance
Holding disclosure · report date 2024-05-10 · row 22
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 22 · Balance 57 F3: Exercisable in full as of the date of this report. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $104.02 · Expires 2032-09-27 | Direct | 125 |
Reported balance
Holding disclosure · report date 2024-05-10 · row 23
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 23 · Balance 125 F3: Exercisable in full as of the date of this report. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $135.52 · Expires 2032-12-28 | Direct | 94 |
Reported balance
Holding disclosure · report date 2024-05-10 · row 24
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 24 · Balance 94 F3: Exercisable in full as of the date of this report. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $83.86 · Expires 2033-03-28 | Direct | 152 |
Reported balance
Holding disclosure · report date 2024-05-10 · row 25
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 25 · Balance 152 F3: Exercisable in full as of the date of this report. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $86.10 | Direct | 684 |
Reported balance
Holding disclosure · report date 2024-05-10 · row 26
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 26 · Balance 684 F3: Exercisable in full as of the date of this report. F8: This option expires on May 8, 2033 or five years following retirement or cessation of services, whichever occurs first. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $74.76 · Expires 2033-06-27 | Direct | 172 |
Reported balance
Holding disclosure · report date 2024-05-10 · row 27
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 27 · Balance 172 F3: Exercisable in full as of the date of this report. |
| Common StockSEC Table I · non-derivative | Direct | 303 |
Reported balance
Holding disclosure · report date 2024-05-10 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 303 |
| Common StockSEC Table I · non-derivative | IndirectBy Benbow Estates, Ltd. | 451 |
Reported balance
Holding disclosure · report date 2024-05-10 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 451 F1: Mr. Frieberg's spouse is the owner of Benbow Estates, Ltd. and Mr. Frieberg is an officer of Benbow Estates, Ltd. Mr. Frieberg disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Gee Eff Services Limited | 920 |
Reported balance
Holding disclosure · report date 2024-05-10 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 920 F2: Mr. Frieberg is the sole owner and President of Gee Eff Services Limited. |
Filing footnotes · ownership attribution and instrument terms
F1: Mr. Frieberg's spouse is the owner of Benbow Estates, Ltd. and Mr. Frieberg is an officer of Benbow Estates, Ltd. Mr. Frieberg disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
F2: Mr. Frieberg is the sole owner and President of Gee Eff Services Limited.
F3: Exercisable in full as of the date of this report.
F4: This option expires on May 14, 2029 or five years following retirement or cessation of services, whichever occurs first.
F5: This option expires on May 12, 2030 or five years following retirement or cessation of services, whichever occurs first.
F6: This option expires on May 9, 2031 or five years following retirement or cessation of services, whichever occurs first.
F7: This option expires on May 9, 2032 or five years following retirement or cessation of services, whichever occurs first.
F8: This option expires on May 8, 2033 or five years following retirement or cessation of services, whichever occurs first.
F9: Pursuant to the Issuer's Director Compensation Plan, in a transaction exempt under Rule 16b-3, the reporting person elected to receive these options in lieu of $8,750 for retainer and meeting fees during the first quarter of 2024. The number of options was calculated in accordance with the Black-Scholes valuation model and all such options are immediately exercisable.
F10: This option was granted pursuant to the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and expires on May 10, 2034 or five years following retirement or cessation of services, whichever occurs first.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 10, 2024 Filed May 14, 2024 16:32 UTC | VACCINEX, INC. VCNX · Entity 9673 | GrantStock Option (Right to Buy) · Derivative | 10,108 | $0.00 Strike: $5.75 | $0.00 |
DisclosureSEC source: 0001062993-24-010179 · form4.xml · derivative · entry 29 Frieberg Jacob B. · CIK 0001748346 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,108 Underlying: Common Stock · 10,108 shares Expires not disclosed F10 · derivative.expiration_date: This option was granted pursuant to the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and expires on May 10, 2034 or five years following retirement or cessation of services, whichever occurs first. Read SEC document |
| May 10, 2024 Filed May 14, 2024 16:32 UTC | VACCINEX, INC. VCNX · Entity 9673 | GrantStock Option (Right to Buy) · Derivative | 2,211 | $3.96 Strike: $5.75 | $8,755.56 |
DisclosureSEC source: 0001062993-24-010179 · form4.xml · derivative · entry 28 Frieberg Jacob B. · CIK 0001748346 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,211 Underlying: Common Stock · 2,211 shares Expires 2034-05-10 F9 · price: Pursuant to the Issuer's Director Compensation Plan, in a transaction exempt under Rule 16b-3, the reporting person elected to receive these options in lieu of $8,750 for retainer and meeting fees during the first quarter of 2024. The number of options was calculated in accordance with the Black-Scholes valuation model and all such options are immediately exercisable. Read SEC document |
| October 23, 2023 Filed Oct 25, 2023 16:30 UTC | VACCINEX, INC. VCNX · Entity 9673 | Disposition to issuerStock Option (Right to Buy) · Derivative | 11,291 | $0.77 Strike: $1.13 | $8,694.07 |
DisclosureSEC source: 0001062993-23-019700 · form4.xml · derivative · entry 28 Frieberg Jacob B. · CIK 0001748346 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,291 shares Expires 2033-09-26 F9 · price: This option was canceled by mutual agreement of the reporting person and Vaccinex, Inc. The reporting person received $8,750 as consideration for the cancellation, which represents the reporting person's retainer and meeting fees during the third quarter of 2023. Read SEC document |
| September 29, 2023 Filed Oct 5, 2023 16:30 UTC | VACCINEX, INC. VCNX · Entity 9673 | GrantStock Option (Right to Buy) · Derivative | 11,291 | $0.77 Strike: $1.13 | $8,694.07 |
DisclosureSEC source: 0001062993-23-019059 · form4.xml · derivative · entry 28 Frieberg Jacob B. · CIK 0001748346 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,291 Underlying: Common Stock · 11,291 shares Expires 2033-09-26 F10 · price: Pursuant to the Issuer's Director Compensation Plan, in a transaction exempt under Rule 16b-3, the reporting person elected to receive these options in lieu of $8,750 for retainer and meeting fees during the third quarter of 2023. The number of options was calculated in accordance with the Black-Scholes valuation model and all such options are immediately exercisable. Read SEC document |
| June 30, 2023 Filed Oct 5, 2023 16:30 UTC | VACCINEX, INC. VCNX · Entity 9673 | GrantStock Option (Right to Buy) · Derivative | 2,414 | $3.62 Strike: $5.34 | $8,738.68 |
DisclosureSEC source: 0001062993-23-019059 · form4.xml · derivative · entry 27 Frieberg Jacob B. · CIK 0001748346 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,414 Underlying: Common Stock · 2,414 shares Expires 2033-06-27 F9 · price: Pursuant to the Issuer's Director Compensation Plan, in a transaction exempt under Rule 16b-3, the reporting person elected to receive these options in lieu of $8,750 for retainer and meeting fees during the second quarter of 2023. The number of options was calculated in accordance with the Black-Scholes valuation model and all such options are immediately exercisable. Read SEC document |
| May 11, 2023 Filed May 15, 2023 16:32 UTC | VACCINEX, INC. VCNX · Entity 9673 | GrantStock Option (Right to Buy) · Derivative | 143,848 | $0.00 Strike: $0.41 | $0.00 |
DisclosureSEC source: 0001062993-23-011115 · form4.xml · derivative · entry 26 Frieberg Jacob B. · CIK 0001748346 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 143,848 Underlying: Common Stock · 143,848 shares Expires not disclosed F8 · derivative.expiration_date: This option was granted pursuant to the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and expires on May 8, 2033 or five years following retirement or cessation of services, whichever occurs first. Read SEC document |
| March 31, 2023 Filed Apr 3, 2023 16:34 UTC | VACCINEX, INC. VCNX · Entity 9673 | GrantStock Option (Right to Buy) · Derivative | 32,107 | $0.27 Strike: $0.40 | $8,668.89 |
DisclosureSEC source: 0001062993-23-008324 · form4.xml · derivative · entry 25 Frieberg Jacob B. · CIK 0001748346 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,107 Underlying: Common Stock · 32,107 shares Expires 2033-03-28 F8 · price: Pursuant to the Issuer's Director Compensation Plan, in a transaction exempt under Rule 16b-3, the reporting person elected to receive these options in lieu of $8,750 for retainer and meeting fees during the first quarter of 2023. The number of options was calculated in accordance with the Black-Scholes valuation model and all such options are immediately exercisable. Read SEC document |
| December 31, 2022 Filed Jan 4, 2023 16:30 UTC | VACCINEX, INC. VCNX · Entity 9673 | GrantStock Option (Right to Buy) · Derivative | 19,852 | $0.44 Strike: $0.65 | $8,734.88 |
DisclosureSEC source: 0001062993-23-000300 · form4.xml · derivative · entry 24 Frieberg Jacob B. · CIK 0001748346 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,852 Underlying: Common Stock · 19,852 shares Expires 2032-12-28 F8 · price: Pursuant to the Issuer's Director Compensation Plan, in a transaction exempt under Rule 16b-3, the reporting person elected to receive these options in lieu of $8,750 for retainer and meeting fees during the fourth quarter of 2022. The number of options was calculated in accordance with the Black-Scholes valuation model and all such options are immediately exercisable. Read SEC document |
| November 23, 2022 Filed Nov 28, 2022 16:33 UTC | VACCINEX, INC. VCNX · Entity 9673 | GrantCommon Stock | 188,928 | $0.53 | $99,999.59 |
DisclosureSEC source: 0001062993-22-022814 · form4.xml · nonDerivative · entry 3 Frieberg Jacob B. · CIK 0001748346 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Gee Eff Services Limited Disclosed balance after: 193,049 F2 · ownership.nature: Mr. Frieberg is the sole owner and President of Gee Eff Services Limited. Read SEC document |
| September 30, 2022 Filed Oct 3, 2022 16:15 UTC | VACCINEX, INC. VCNX · Entity 9673 | GrantStock Option (Right to Buy) · Derivative | 26,260 | $0.00 Strike: $0.50 | $0.00 |
DisclosureSEC source: 0001062993-22-020146 · form4.xml · derivative · entry 23 Frieberg Jacob B. · CIK 0001748346 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,260 Underlying: Common Stock · 26,260 shares Expires 2032-09-27 F8 · price: Pursuant to the Issuer's Director Compensation Plan, in a transaction exempt under Rule 16b-3, the reporting person elected to receive these options in lieu of $8,750 for retainer and meeting fees during the third quarter of 2022. The number of options was calculated in accordance with the Black-Scholes valuation model and all such options are immediately exercisable. Read SEC document |
| June 30, 2022 Filed Jul 1, 2022 16:30 UTC | VACCINEX, INC. VCNX · Entity 9673 | GrantStock Option (Right to Buy) · Derivative | 12,064 | $0.00 Strike: $1.08 | $0.00 |
DisclosureSEC source: 0001062993-22-015746 · form4.xml · derivative · entry 22 Frieberg Jacob B. · CIK 0001748346 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,064 Underlying: Common Stock · 12,064 shares Expires 2032-06-27 F8 · price: Pursuant to the Issuer's Director Compensation Plan, in a transaction exempt under Rule 16b-3, the reporting person elected to receive these options in lieu of $8,750 for retainer and meeting fees during the second quarter of 2022. The number of options was calculated in accordance with the Black-Scholes valuation model and all such options are immediately exercisable. Read SEC document |
| May 12, 2022 Filed May 13, 2022 16:37 UTC | VACCINEX, INC. VCNX · Entity 9673 | GrantStock Option (Right to Buy) · Derivative | 53,254 | $0.00 Strike: $1.12 | $0.00 |
DisclosureSEC source: 0001062993-22-012384 · form4.xml · derivative · entry 21 Frieberg Jacob B. · CIK 0001748346 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,254 Underlying: Common Stock · 53,254 shares Expires not disclosed F7 · derivative.expiration_date: This option was granted pursuant to the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and expires on May 9, 2032 or five years following retirement or cessation of services, whichever occurs first. Read SEC document |
| March 31, 2022 Filed Apr 4, 2022 16:30 UTC | VACCINEX, INC. VCNX · Entity 9673 | GrantStock Option (Right to Buy) · Derivative | 10,032 | $0.00 Strike: $1.32 | $0.00 |
DisclosureSEC source: 0001062993-22-009441 · form4.xml · derivative · entry 20 Frieberg Jacob B. · CIK 0001748346 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,032 Underlying: Common Stock · 10,032 shares Expires 2032-03-28 F7 · price: Pursuant to the Issuer's Director Compensation Plan, in a transaction exempt under Rule 16b-3, the reporting person elected to receive these options in lieu of $8,750 for retainer and meeting fees during the first quarter of 2022. The number of options was calculated in accordance with the Black-Scholes valuation model and all such options are immediately exercisable. Read SEC document |
| January 27, 2022 Filed Jan 31, 2022 16:26 UTC | VACCINEX, INC. VCNX · Entity 9673 | PurchaseCommon Stock | 90,090 | $1.11 | $99,999.90 |
DisclosureSEC source: 0001062993-22-001868 · form4.xml · nonDerivative · entry 2 Frieberg Jacob B. · CIK 0001748346 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Benbow Estates, Ltd. Disclosed balance after: 94,510 F1 · shares: Mr. Frieberg's spouse is the owner of Benbow Estates, Ltd. and Mr. Frieberg is an officer of Benbow Estates, Ltd. Mr. Frieberg disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. F1 · balance_after: Mr. Frieberg's spouse is the owner of Benbow Estates, Ltd. and Mr. Frieberg is an officer of Benbow Estates, Ltd. Mr. Frieberg disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. F1 · ownership.nature: Mr. Frieberg's spouse is the owner of Benbow Estates, Ltd. and Mr. Frieberg is an officer of Benbow Estates, Ltd. Mr. Frieberg disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. Read SEC document |
| December 31, 2021 Filed Jan 3, 2022 16:17 UTC | VACCINEX, INC. VCNX · Entity 9673 | GrantStock Option (Right to Buy) · Derivative | 12,856 | $0.68 Strike: $1.04 | $8,742.08 |
DisclosureSEC source: 0001062993-22-000063 · form4.xml · derivative · entry 19 Frieberg Jacob B. · CIK 0001748346 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,856 Underlying: Common Stock · 12,856 shares Expires 2031-12-29 F7 · price: Pursuant to the Issuer's Director Compensation Program, in a transaction exempt under Rule 16b-3, the reporting person elected to receive these options in lieu of $8,750 for retainer and meeting fees during the fourth quarter of 2021. The number of options was calculated in accordance with the Black-Scholes valuation model and all such options are immediately exercisable. Read SEC document |
| September 30, 2021 Filed Oct 4, 2021 16:22 UTC | VACCINEX, INC. VCNX · Entity 9673 | GrantStock Option (Right to Buy) · Derivative | 6,233 | $0.00 Strike: $2.16 | $0.00 |
DisclosureSEC source: 0000891839-21-000316 · edgar.xml · derivative · entry 18 Frieberg Jacob B. · CIK 0001748346 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,233 Underlying: Common Stock · 6,233 shares Expires not disclosed F8 · derivative.expiration_date: This option was granted pursuant to the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, expires on September 28, 2031. Read SEC document |
| June 30, 2021 Filed Jul 2, 2021 16:07 UTC | VACCINEX, INC. VCNX · Entity 9673 | GrantStock Option (Right to Buy) · Derivative | 4,804 | $0.00 Strike: $2.80 | $0.00 |
DisclosureSEC source: 0000891839-21-000247 · edgar.xml · derivative · entry 17 Frieberg Jacob B. · CIK 0001748346 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,804 Underlying: Common Stock · 4,804 shares Expires not disclosed F7 · derivative.expiration_date: This option was granted pursuant to the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, expires on June 28, 2031. Read SEC document |
| June 25, 2021 Filed Jun 28, 2021 16:31 UTC | VACCINEX, INC. VCNX · Entity 9673 | ConversionOption (Right to Acquire) · Derivative | 75,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000891839-21-000234 · edgar.xml · derivative · entry 6 Frieberg Jacob B. · CIK 0001748346 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Gee Eff Services Limited Disclosed balance after: 0 Underlying: Common Stock · 4,121 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Partnership interests in VX3 (DE) LP, or VX3 were exchanged into shares of Common Stock on a 1-for-0.05495 basis. F2 · derivative.exercise_price: Partnership interests in VX3 (DE) LP, or VX3 were exchanged into shares of Common Stock on a 1-for-0.05495 basis. F2 · price: Partnership interests in VX3 (DE) LP, or VX3 were exchanged into shares of Common Stock on a 1-for-0.05495 basis. F2 · derivative.exercise_date: Partnership interests in VX3 (DE) LP, or VX3 were exchanged into shares of Common Stock on a 1-for-0.05495 basis. F2 · derivative.expiration_date: Partnership interests in VX3 (DE) LP, or VX3 were exchanged into shares of Common Stock on a 1-for-0.05495 basis. F4 · ownership.nature: Mr. Frieberg is the sole owner and President of Gee Eff Services Limited. Read SEC document |
| June 25, 2021 Filed Jun 28, 2021 16:31 UTC | VACCINEX, INC. VCNX · Entity 9673 | ConversionOption (Right to Acquire) · Derivative | 44,200 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000891839-21-000234 · edgar.xml · derivative · entry 5 Frieberg Jacob B. · CIK 0001748346 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Benbow Estates, Ltd. Disclosed balance after: 0 Underlying: Common Stock · 4,420 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Limited partnership units of Vaccinex Products, LP were exchanged into shares of Common Stock on a 1-for-10 basis. F1 · derivative.exercise_price: Limited partnership units of Vaccinex Products, LP were exchanged into shares of Common Stock on a 1-for-10 basis. F1 · price: Limited partnership units of Vaccinex Products, LP were exchanged into shares of Common Stock on a 1-for-10 basis. F1 · derivative.exercise_date: Limited partnership units of Vaccinex Products, LP were exchanged into shares of Common Stock on a 1-for-10 basis. F1 · derivative.expiration_date: Limited partnership units of Vaccinex Products, LP were exchanged into shares of Common Stock on a 1-for-10 basis. F3 · ownership.nature: Mr. Frieberg's spouse is the owner of Benbow Estates, Ltd. and Mr. Frieberg is an officer of Benbow Estates, Ltd. Mr. Frieberg disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. Read SEC document |
| June 25, 2021 Filed Jun 28, 2021 16:31 UTC | VACCINEX, INC. VCNX · Entity 9673 | ConversionOption (Right to Acquire) · Derivative | 44,200 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000891839-21-000234 · edgar.xml · derivative · entry 4 Frieberg Jacob B. · CIK 0001748346 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,420 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Limited partnership units of Vaccinex Products, LP were exchanged into shares of Common Stock on a 1-for-10 basis. F1 · derivative.exercise_price: Limited partnership units of Vaccinex Products, LP were exchanged into shares of Common Stock on a 1-for-10 basis. F1 · price: Limited partnership units of Vaccinex Products, LP were exchanged into shares of Common Stock on a 1-for-10 basis. F1 · derivative.exercise_date: Limited partnership units of Vaccinex Products, LP were exchanged into shares of Common Stock on a 1-for-10 basis. F1 · derivative.expiration_date: Limited partnership units of Vaccinex Products, LP were exchanged into shares of Common Stock on a 1-for-10 basis. Read SEC document |
| June 25, 2021 Filed Jun 28, 2021 16:31 UTC | VACCINEX, INC. VCNX · Entity 9673 | ConversionCommon Stock | 4,121 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000891839-21-000234 · edgar.xml · nonDerivative · entry 3 Frieberg Jacob B. · CIK 0001748346 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Gee Eff Services Limited Disclosed balance after: 4,121 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Partnership interests in VX3 (DE) LP, or VX3 were exchanged into shares of Common Stock on a 1-for-0.05495 basis. F4 · ownership.nature: Mr. Frieberg is the sole owner and President of Gee Eff Services Limited. Read SEC document |
| June 25, 2021 Filed Jun 28, 2021 16:31 UTC | VACCINEX, INC. VCNX · Entity 9673 | ConversionCommon Stock | 4,420 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000891839-21-000234 · edgar.xml · nonDerivative · entry 2 Frieberg Jacob B. · CIK 0001748346 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Benbow Estates, Ltd. Disclosed balance after: 4,420 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Limited partnership units of Vaccinex Products, LP were exchanged into shares of Common Stock on a 1-for-10 basis. F3 · ownership.nature: Mr. Frieberg's spouse is the owner of Benbow Estates, Ltd. and Mr. Frieberg is an officer of Benbow Estates, Ltd. Mr. Frieberg disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. Read SEC document |
| June 25, 2021 Filed Jun 28, 2021 16:31 UTC | VACCINEX, INC. VCNX · Entity 9673 | ConversionCommon Stock | 4,420 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000891839-21-000234 · edgar.xml · nonDerivative · entry 1 Frieberg Jacob B. · CIK 0001748346 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,286 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Limited partnership units of Vaccinex Products, LP were exchanged into shares of Common Stock on a 1-for-10 basis. Read SEC document |
| May 11, 2021 Filed May 12, 2021 16:22 UTC | VACCINEX, INC. VCNX · Entity 9673 | GrantStock Option (Right to Buy) · Derivative | 28,586 | $0.00 Strike: $2.15 | $0.00 |
DisclosureSEC source: 0000891839-21-000135 · edgar.xml · derivative · entry 17 Frieberg Jacob B. · CIK 0001748346 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,586 Underlying: Common Stock · 28,586 shares Expires not disclosed F8 · derivative.expiration_date: This option was granted pursuant to the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and expires on May 9, 2031 or five years following retirement or cessation of services, whichever occurs first. Read SEC document |
| March 31, 2021 Filed Apr 1, 2021 16:23 UTC | VACCINEX, INC. VCNX · Entity 9673 | GrantStock Option (Right to Buy) · Derivative | 4,535 | $0.00 Strike: $2.98 | $0.00 |
DisclosureSEC source: 0000891839-21-000089 · edgar.xml · derivative · entry 16 Frieberg Jacob B. · CIK 0001748346 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,535 Underlying: Common Stock · 4,535 shares Expires 2031-03-31 F8 · price: Pursuant to the Issuer's Director Compensation Program, in a transaction exempt under Rule 16b-3, the reporting person elected to receive these options in lieu of $8,750 for retainer and meeting fees during the first quarter of 2021. The number of options was calculated in accordance with the Black-Scholes valuation model and all such options are immediately exercisable. Read SEC document |
| December 31, 2020 Filed Jan 4, 2021 16:32 UTC | VACCINEX, INC. VCNX · Entity 9673 | GrantStock Option (Right to Buy) · Derivative | 6,545 | $0.00 Strike: $2.07 | $0.00 |
DisclosureSEC source: 0000891839-21-000004 · edgar.xml · derivative · entry 15 Frieberg Jacob B. · CIK 0001748346 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,545 Underlying: Common Stock · 6,545 shares Expires 2030-12-29 F8 · price: Pursuant to the Issuer's Director Compensation Program, in a transaction exempt under Rule 16b-3, the reporting person elected to receive these options in lieu of $8,750 for retainer and meeting fees during the fourth quarter of 2020. The number of options was calculated in accordance with the Black-Scholes valuation model and all such options are immediately exercisable. Read SEC document |
| September 30, 2020 Filed Oct 1, 2020 16:31 UTC | VACCINEX, INC. VCNX · Entity 9673 | GrantStock Option (Right to Buy) · Derivative | 7,626 | $0.00 Strike: $1.78 | $0.00 |
DisclosureSEC source: 0000891839-20-000296 · edgar.xml · derivative · entry 14 Frieberg Jacob B. · CIK 0001748346 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,626 Underlying: Common Stock · 7,626 shares Expires 2030-09-28 F8 · price: Pursuant to the Issuer's Director Compensation Program, in a transaction exempt under Rule 16b-3, the reporting person elected to receive these options in lieu of $8,750 for retainer and meeting fees during the third quarter of 2020. The number of options was calculated in accordance with the Black-Scholes valuation model and all such options are immediately exercisable. Read SEC document |
| June 30, 2020 Filed Jul 2, 2020 16:30 UTC | VACCINEX, INC. VCNX · Entity 9673 | GrantStock Option (Right to Buy) · Derivative | 3,756 | $0.00 Strike: $3.61 | $0.00 |
DisclosureSEC source: 0000891839-20-000205 · edgar.xml · derivative · entry 13 Frieberg Jacob B. · CIK 0001748346 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,756 Underlying: Common Stock · 3,756 shares Expires 2030-06-28 F8 · price: Pursuant to the Issuer's Director Compensation Program, in a transaction exempt under Rule 16b-3, the reporting person elected to receive these options in lieu of $8,750 for retainer and meeting fees during the second quarter of 2020. The number of options was calculated in accordance with the Black-Scholes valuation model and all such options are immediately exercisable. Read SEC document |
| May 14, 2020 Filed May 18, 2020 16:23 UTC | VACCINEX, INC. VCNX · Entity 9673 | GrantStock Option (Right to Buy) · Derivative | 15,679 | $0.00 Strike: $3.95 | $0.00 |
DisclosureSEC source: 0000891839-20-000122 · edgar.xml · derivative · entry 12 Frieberg Jacob B. · CIK 0001748346 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,679 Underlying: Common Stock · 15,679 shares Expires not disclosed F7 · derivative.expiration_date: This option was granted pursuant to the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and expires on May 12, 2030 or five years following retirement or cessation of services, whichever occurs first. Read SEC document |
| March 31, 2020 Filed Apr 1, 2020 16:18 UTC | VACCINEX, INC. VCNX · Entity 9673 | GrantStock Option (Right to Buy) · Derivative | 3,336 | $0.00 Strike: $4.00 | $0.00 |
DisclosureSEC source: 0000891839-20-000086 · edgar.xml · derivative · entry 11 Frieberg Jacob B. · CIK 0001748346 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,336 Underlying: Common Stock · 3,336 shares Expires 2030-03-29 F8 · price: Pursuant to the Issuer's Director Compensation Program, in a transaction exempt under Rule 16b-3, the reporting person elected to receive these options in lieu of $8,750 for retainer and meeting fees during the first quarter of 2020. The number of options was calculated in accordance with the Black-Scholes valuation model and all such options are immediately exercisable. Read SEC document |
| January 23, 2020 Filed Jan 27, 2020 16:24 UTC | VACCINEX, INC. VCNX · Entity 9673 | PurchaseCommon Stock | 39,292 | $5.09 | $199,996.28 |
DisclosureSEC source: 0000891839-20-000033 · edgar.xml · nonDerivative · entry 1 Frieberg Jacob B. · CIK 0001748346 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,292 Read SEC document |
| December 31, 2019 Filed Jan 6, 2020 16:33 UTC | VACCINEX, INC. VCNX · Entity 9673 | GrantStock Option (Right to Buy) · Derivative | 2,737 | $0.00 Strike: $4.85 | $0.00 |
DisclosureSEC source: 0000891839-20-000017 · edgar.xml · derivative · entry 8 Frieberg Jacob B. · CIK 0001748346 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,737 Underlying: Common Stock · 2,737 shares Expires 2029-12-28 F7 · price: Pursuant to the Issuer's Director Compensation Program, in a transaction exempt under Rule 16b-3, the reporting person elected to receive these options in lieu of $8,750 for retainer and meeting fees during the fourth quarter of 2019. The number of options was calculated in accordance with the Black-Scholes valuation model and all such options are immediately exercisable. Read SEC document |
| September 30, 2019 Filed Oct 4, 2019 10:56 UTC | VACCINEX, INC. VCNX · Entity 9673 | GrantStock Option (Right to Buy) · Derivative | 1,856 | $0.00 Strike: $7.17 | $0.00 |
DisclosureSEC source: 0001209191-19-052505 · doc4.xml · derivative · entry 7 Frieberg Jacob B. · CIK 0001748346 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,856 Underlying: Common Stock · 1,856 shares Expires 2019-09-27 F7 · price: Pursuant to the Issuer's Director Compensation Program, in a transaction exempt under Rule 16b-3, the reporting person elected to receive these options in lieu of $8,750 for retainer and meeting fees during the third quarter of 2019. The number of options was calculated in accordance with the Black-Scholes valuation model and all of such options are immediately exercisable. Read SEC document |
| September 30, 2019 Filed Jan 6, 2020 16:30 UTC Amendment | VACCINEX, INC. VCNX · Entity 9673 | GrantStock Option (Right to Buy) · Derivative | 1,856 | $0.00 Strike: $7.17 | $0.00 |
DisclosureSEC source: 0000891839-20-000015 · edgar.xml · derivative · entry 1 Frieberg Jacob B. · CIK 0001748346 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,856 Underlying: Common Stock · 1,856 shares Expires 2029-09-27 F2 · price: Pursuant to the Issuer's Director Compensation Program, in a transaction exempt under Rule 16b-3, the reporting person elected to receive these options in lieu of $8,750 for retainer and meeting fees during the third quarter of 2019. The number of options was calculated in accordance with the Black-Scholes valuation model and all of such options are immediately exerccisable. F1 · derivative.expiration_date: The original Form 4 contained an incorrect expiration date for these options. This amendment is being filed to correct the expiration date. Read SEC document |
| June 30, 2019 Filed Jan 15, 2020 16:20 UTC | VACCINEX, INC. VCNX · Entity 9673 | GrantStock Option (Right to Buy) · Derivative | 2,385 | $0.00 Strike: $5.52 | $0.00 |
DisclosureSEC source: 0000891839-20-000029 · edgar.xml · derivative · entry 7 Frieberg Jacob B. · CIK 0001748346 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,385 Underlying: Common Stock · 2,385 shares Expires 2029-06-29 F7 · price: Pursuant to the Issuer's Director Compensation Program, in a transaction exempt under Rule 16b-3, the reporting person elected to receive these options in lieu of $8,750 for retainer and meeting fees during the second quarter of 2019. The number of options was calculated in accordance with the Black-Scholes valuation model and all such options are immediately exercisable. Read SEC document |
| May 15, 2019 Filed May 17, 2019 16:44 UTC | VACCINEX, INC. VCNX · Entity 9673 | GrantStock Option (Right to Buy) · Derivative | 7,718 | $0.00 Strike: $7.78 | $0.00 |
DisclosureSEC source: 0000891839-19-000072 · edgar.xml · derivative · entry 6 Frieberg Jacob B. · CIK 0001748346 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,718 Underlying: Common Stock · 7,718 shares Expires not disclosed F6 · derivative.expiration_date: This option was granted pursuant to the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and expires on May 14, 2029 or five years following retirement or cessation of services, whichever occurs first. Read SEC document |
| March 31, 2019 Filed Apr 2, 2019 16:28 UTC | VACCINEX, INC. VCNX · Entity 9673 | GrantStock Option (Right to Buy) · Derivative | 2,501 | $0.00 Strike: $5.26 | $0.00 |
DisclosureSEC source: 0000891839-19-000057 · edgar.xml · derivative · entry 5 Frieberg Jacob B. · CIK 0001748346 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,501 Underlying: Common Stock · 2,501 shares Expires 2029-03-30 F6 · shares: Pursuant to the Issuer's Director Compensation Program, in a transaction exempt under Rule 16b-3, the reporting person elected to receive these options in lieu of the $8,750 cash compensation earned in the first quarter of 2019 for service as a member of the Issuer's board of directors. The number of options was calculated in accordance wih the Black-Scholes valuation model and all of such options are immediately exercisable. F6 · price: Pursuant to the Issuer's Director Compensation Program, in a transaction exempt under Rule 16b-3, the reporting person elected to receive these options in lieu of the $8,750 cash compensation earned in the first quarter of 2019 for service as a member of the Issuer's board of directors. The number of options was calculated in accordance wih the Black-Scholes valuation model and all of such options are immediately exercisable. F6 · derivative.exercise_date: Pursuant to the Issuer's Director Compensation Program, in a transaction exempt under Rule 16b-3, the reporting person elected to receive these options in lieu of the $8,750 cash compensation earned in the first quarter of 2019 for service as a member of the Issuer's board of directors. The number of options was calculated in accordance wih the Black-Scholes valuation model and all of such options are immediately exercisable. Read SEC document |
| August 13, 2018 Filed Aug 15, 2018 16:50 UTC | VACCINEX, INC. VCNX · Entity 9673 | OtherOption (Right to Acquire) · Derivative | 75,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001123292-18-000929 · edgar.xml · derivative · entry 1 Frieberg Jacob B. · CIK 0001748346 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Gee Eff Services Limited Disclosed balance after: 75,000 Underlying: Common Stock · 4,121 shares Expires not disclosed F1 · security: Partnership interests in VX3 (DE) LP, or VX3, which are exchangeable into shares of Common Stock on a 1-for-0.05495 basis at the holder's option. On August 13, 2018, Gee Eff Services Limited entered into an exchange agreement with the Issuer and the other partners of VX3 that provides each VX3 partner the right to exchange all, but not less than all, of its partnership interests in VX3 for shares of Common Stock. The option has no expiration date. F1 · derivative.exercise_price: Partnership interests in VX3 (DE) LP, or VX3, which are exchangeable into shares of Common Stock on a 1-for-0.05495 basis at the holder's option. On August 13, 2018, Gee Eff Services Limited entered into an exchange agreement with the Issuer and the other partners of VX3 that provides each VX3 partner the right to exchange all, but not less than all, of its partnership interests in VX3 for shares of Common Stock. The option has no expiration date. F1 · kind: Partnership interests in VX3 (DE) LP, or VX3, which are exchangeable into shares of Common Stock on a 1-for-0.05495 basis at the holder's option. On August 13, 2018, Gee Eff Services Limited entered into an exchange agreement with the Issuer and the other partners of VX3 that provides each VX3 partner the right to exchange all, but not less than all, of its partnership interests in VX3 for shares of Common Stock. The option has no expiration date. F1 · price: Partnership interests in VX3 (DE) LP, or VX3, which are exchangeable into shares of Common Stock on a 1-for-0.05495 basis at the holder's option. On August 13, 2018, Gee Eff Services Limited entered into an exchange agreement with the Issuer and the other partners of VX3 that provides each VX3 partner the right to exchange all, but not less than all, of its partnership interests in VX3 for shares of Common Stock. The option has no expiration date. F1 · derivative.exercise_date: Partnership interests in VX3 (DE) LP, or VX3, which are exchangeable into shares of Common Stock on a 1-for-0.05495 basis at the holder's option. On August 13, 2018, Gee Eff Services Limited entered into an exchange agreement with the Issuer and the other partners of VX3 that provides each VX3 partner the right to exchange all, but not less than all, of its partnership interests in VX3 for shares of Common Stock. The option has no expiration date. F1 · derivative.expiration_date: Partnership interests in VX3 (DE) LP, or VX3, which are exchangeable into shares of Common Stock on a 1-for-0.05495 basis at the holder's option. On August 13, 2018, Gee Eff Services Limited entered into an exchange agreement with the Issuer and the other partners of VX3 that provides each VX3 partner the right to exchange all, but not less than all, of its partnership interests in VX3 for shares of Common Stock. The option has no expiration date. F2 · ownership.nature: The reporting person is the sole owner and President of Gee Eff Services Limited. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.